WuXi Biologics (Cayman) Inc., a next-day disclosure report filed March 28, 2024, shows that the company made multiple share repurchases between December 7, 2023 and March 28, 2024, but did not write them off. During this period, the company repurchased 85,907,000 shares, representing 2.0221% of the issued shares. The most recent repurchase took place on March 28, 2024. 3,490,000 shares were repurchased on that date for a total amount of HKD 49,868,280, with a price of HKD 13.8 to HKD 14.38 per share. In addition, on March 27 and 28, 2024, the Company issued 131,000 shares and 107,000 shares under the Share Option Scheme at HKD 2.51 and HKD 2.13, respectively, at a discount of more than 80% from the market price. As of March 28, 2024, Pharmaceuticals had issued 4,258,551,066 shares outstanding.

WuXi Biologics (Cayman) Inc., a next-day disclosure report filed March 28, 2024, shows that the company made multiple share repurchases between December 7, 2023 and March 28, 2024, but did not write them off. During this period, the company repurchased 85,907,000 shares, representing 2.0221% of the issued shares. The most recent repurchase took place on March 28, 2024. 3,490,000 shares were repurchased on that date for a total amount of HKD 49,868,280, with a price of HKD 13.8 to HKD 14.38 per share. In addition, on March 27 and 28, 2024, the Company issued 131,000 shares and 107,000 shares under the Share Option Scheme at HKD 2.51 and HKD 2.13, respectively, at a discount of more than 80% from the market price. As of March 28, 2024, Pharmaceuticals had issued 4,258,551,066 shares outstanding.